Answer
Jun 12, 2025 - 12:13 PM
Abemaciclib, a CDK4/6 inhibitor used in the treatment of certain types of breast cancer, is most commonly associated with gastrointestinal adverse events, particularly diarrhea. This side effect is often the most frequently reported and can be significant, requiring proactive management such as dose adjustments or supportive care to ensure patient comfort and adherence to the treatment regimen. Other common adverse events include neutropenia and fatigue.
